Beijing Genomics Institute (BGI)

BGI ((BGI China) was founded in 1999 with the vision of using genomics to benefit mankind and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated over 2,137 publications, many in top-tier journals such as Nature and Science.

The company also contributes to scientific communication by publishing the international research journal GigaScience.

BGI's distinguished achievements have made a significant contribution to the development of genomics throughout the world. BGI's goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry's broadest array of leading technologies, including BGI's own BGISEQ sequencing platform, economies of scale, and expert bioinformatics resources.

BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. BGI's services and solutions are available in more than 60 countries and regions around the world.

Vision

Trans-omics for a better life.

Mission

A combination of its high-throughput, cost-effective genomics platform, its large sample collection and storage capability, in-depth bioinformatics analysis, a core commitment to education and media liaison, a team of talents to support its scientific research program, has made BGI a unique entity dedicated to ensuring that omics science and technology can be made to work for the benefit of everyone.